The Additive Antinociceptive Interaction Between WIN 55,212-2, a Cannabinoid Agonist, and Ketorolac
- 1 February 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anesthesia & Analgesia
- Vol. 102 (2), 443-447
- https://doi.org/10.1213/01.ane.0000194587.94260.1d
Abstract
Combinations of nonsteroidal antiinflammatory drugs (NSAIDs) and opioids are widespread in the management of pain, allowing better analgesia with reduced side effects. Cannabinoids are promising analgesic drugs that have pharmacological properties similar to those of opioids. However, the beneficial effects of cannabinoids for pain treatment are counterbalanced by their psychotomimetic side effects. We designed the present study to evaluate the antinociceptive interaction between cannabinoids and NSAIDs in mice, using the acetic acid-induced writhing test and tail-flick test. Interactions were analyzed using isobolographic analysis. WIN 55,212-2, a cannabinoid agonist, and the NSAID ketorolac, either alone or in combination, produced dose-dependent antinociception in the writhing test. Isobolographic analysis showed additive interactions between WIN 55,212-2 and ketorolac when they were coadministered systemically. Ketorolac is inactive in the radiant heat tail-flick test in which WIN 55,212-2 was active. Ketorolac did not influence WIN 55,212-2–induced antinociception in the tail-flick test. This study demonstrated an additive antinociceptive interaction between WIN 55,212-2 and ketorolac in an inflammatory visceral pain model. The combination of cannabinoids and NSAIDs may have utility in the pharmacotherapy of pain.This publication has 24 references indexed in Scilit:
- Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsyNeuropharmacology, 2005
- Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of postoperative pain: A double-blind, placebo- and active-controlled parallel-group studyClinical Therapeutics, 2004
- Lack of cross-tolerance to the antinociceptive effects of systemic and topical cannabinoids in morphine-tolerant miceNeuroscience Letters, 2004
- The good and the bad effects of (−) trans-delta-9-tetrahydrocannabinol (Δ9-THC) on humansToxicon, 2004
- Topical cannabinoid enhances topical morphine antinociceptionPain, 2003
- Topical cannabinoid antinociception: synergy with spinal sitesPain, 2003
- Effect of the inhibition of serotonin biosynthesis on the antinociception induced by nonsteroidal anti-inflammatory drugsBrain Research Bulletin, 2003
- Cannabinoid analgesiaPharmacology & Therapeutics, 2002
- Pharmacology of oral combination analgesics: rational therapy for painJournal of Clinical Pharmacy & Therapeutics, 2001
- Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like DrugsNature New Biology, 1971